Lexaria Bioscience Corp. LXRP Archives - Page 14 of 27

MondayNov 26, 2018 10:18 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Submits Health Canada Research Application, Appoints Chief Legal Officer

Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) this morning announced its submittal of a Health Canada research application, as well as the appointment of Dr. Ed Ergenzinger to its executive team. The company’s research application, submitted under Health Canada's Cannabis Tracking and Licensing System, is for the operation of an R&D laboratory to work with cannabinoids within Lexaria's under construction Kelowna-based head office. According to the update, the laboratory will enhance Lexaria's ability to formulate various products, which may contain cannabinoids or other controlled substances, for analytical purposes. In addition, the company appointed…

TuesdayNov 20, 2018 2:49 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Raises $1.5M in Private Placement to Fund Canadian Lab

British Columbia, Canada-based Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is a biotechnology company and developer of technology which has demonstrated faster and more effective delivery of cannabinoids and nicotine. Recently, LXRP raised funds through a non-brokered private placement that it intends to use toward the construction of a new Canadian lab, research & development and general corporate purposes. A recent article discussing the company reads, “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has raised, in a non-brokered private placement, a total of $1,515,440. Net proceeds will be used for construction of a new lab in Canada, LXRP-driven R&D and general…

WednesdayNov 14, 2018 12:09 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Grows Stronger with Patents and Third-Party Partners

Improving the quality, taste and effectiveness of cannabis products with DehydraTECH Recently granted two new U.S. patents, with over 50 additional patent applications filed worldwide Applications span a wide range of products as the company out-licenses IP to third-party partners through a royalty model Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is using its DehydraTECH to increase the quality, taste and effectiveness of cannabis products. Lexaria’s revolutionary drug delivery platform is disrupting the way cannabidiol enters the bloodstream. Rather than relying on the traditional methods of inhalation, which has harmful lasting impact on a person’s health, DehydraTECH allows for a…

TuesdayNov 13, 2018 9:28 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Launches New Ready-mix Hemp Supplement Powder, ChrgD+

Drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced the launch of ChrgD+, a water-soluble, ready-mix hemp supplement powder packet formulation containing 2 grams of virtually flavorless and odorless powder per pouch. ChrgD+ integrates multi-spectrum hemp oil processed using Lexaria’s patented DehydraTECH technology, permitting effective delivery of hemp oil into any hot or cold beverage. To create the ChrgD+ premium brand, the company engaged Cultivating Wellness Inc. Tens of thousands of retail buyers in c-stores, grocery chains, specialty retail, and national accounts are reachable through Cultivating Wellness' distribution network. Additionally, the company reported that it will…

ThursdayNov 08, 2018 9:42 am

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Private Placement Raises Gross Proceeds of $1.5M; Funds Allocated for Canadian Lab, R&D

Increased size of non-brokered private placement raises gross proceeds of $1,515,440, to be used to fund construction of new Canadian lab, LXRP's R&D and general corporate purposes LXRP has received two new U.S. patents related to cannabinoid infused beverage compositions using DehydraTECH; the company is a drug delivery innovator The company has expanded its IP portfolio, giving it a total of 10 patents in its first family in the U.S. and Australia; it has 50 patent applications globally and out-licenses its technology Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has raised, in a non-brokered private placement, a total of $1,515,440.…

WednesdayNov 07, 2018 1:47 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Continues to Grow International IP Portfolio

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is unwavering in its commitment to build its strategic intellectual property (“IP”) portfolio. Recently, LXRP was granted two new U.S. patents regarding cannabinoid-infused beverage compositions using its DehydraTECH ingestion technology platform. A recent article discussing the company reads, “LXRP has now filed a total of more than 50 patent applications across 10 current patent families. It is preparing applications for at least six more patents that will each form the basis for a separate patent family. It expects to file them before the end of this year, giving it management over a total of…

FridayNov 02, 2018 11:29 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Focusing on its New Subsidiaries and Intellectual Property

Lexaria has its patented DehydraTECH drug delivery platform The company’s technology is a complementary layer that works with the other research being done on cannabinoids Lexaria has a robust IP portfolio and four new subsidiary companies A drug delivery platform pioneer, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its DehydraTECH technology. The company’s technology changes the way in which edible cannabinoids absorb into the body. The DehydraTECH drug delivery platform is patented for cannabidiol and all other non-psychoactive cannabinoids and enables the transportation of bioactive substances via oral ingestion. A research-driven enterprise, Lexaria Bioscience is based…

MondayOct 29, 2018 1:20 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Holds Robust IP Portfolio Protecting DehydraTECH Technology

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) drug delivery platform DehydraTECH employs its patented technology to improve bio-absorption and bioavailability of active ingredients while covering unpleasant tastes. A recent article discussing the company’s technology reads, “Lexaria’s disruptive DehydraTECH drug delivery platform is protected by a robust suite of patents granted or pending worldwide. It has been proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules – such as those contained in cannabinoids (CBD), nicotine, non-steroidal anti-inflammatory drugs (NSAIDs) and other molecules. DehydraTECH offers a healthier, oral ingestion…

WednesdayOct 24, 2018 10:36 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives Two US Patents, Bringing Total to 10 in First Patent Family across US and Australia

The two new patents are related to certain cannabinoid-infused beverage compositions using LXRP’s DehydraTECH technology Globally, LXRP has filed some 50 patent applications as the company expands its IP portfolio; LXRP hopes to receive two more granted patents from Australia by year end, giving it 12 in total LXRP out-licenses its technology, which promotes healthier and faster ingestion; the company seeks accelerated patent application examinations in Australia based on the U.S. patents Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has been granted two new U.S. patents based on cannabinoid-infused beverage compositions using its DehydraTECH ingestion technology platform. The company is…

TuesdayOct 23, 2018 10:46 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Discusses New Subsidiaries, Intellectual Property in Interview on Uptick Newswire’s Stock Day Podcast

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator that has developed and out-licenses its disruptive delivery technology, was recently featured on Uptick Newswire’s Stock Day Podcast. Chairman of the Board and CEO Chris Bunka provided an update regarding Lexaria’s licenses and technology. “Lexaria has been somewhat of a pioneer in this aspect of the business. We have been beating the drum on intellectual property since we began in 2014,” Bunka stated in the interview. “We now have over 50 patents outstanding in over 40 countries around the world. Our IP suite is one of the biggest and…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP